Durvalumab vs Ipilimumab

Durvalumab vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Durvalumab and Ipilimumab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Ipilimumab — 14.7 days.

Chemical Properties

Type: Durvalumab — Antibody; Ipilimumab — Antibody.